GILD vs MRNA Comparison: AI Score, Valuation, Performance and Upside
Compare Gilead and Moderna by revenue durability, pipeline diversification, cash generation vs cash burn, platform reinvestment, and which large biotech strategy — franchise cash flow or platform moonshot — offers better returns.
Use this Gilead Sciences vs Moderna comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
GILD holds the edge across 3 of 5 key metrics in this comparison. MRNA has delivered stronger 1-year price return (+58.98% vs +14.23%), though GILD has the better forward P/E setup (13.83x vs -15.03x for MRNA). On fundamentals, MRNA is growing revenue faster (260.20%), while GILD maintains the higher operating margin (39.28%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for GILD (+17.89%) than for MRNA (-21.93%).
| Metric | GILD | MRNA |
|---|---|---|
| AI score | 41.9 | 44.5 |
| AI rank | #960 | #801 |
| Latest close | $129.31 | $54.07 |
| 1M return | +3.32% | -10.51% |
| 6M return | -4.87% | +11.00% |
| 1Y return | +14.23% | +58.98% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GILD | MRNA |
|---|---|---|
| 1Y ago | $11.13K (+11.3%) started 2025-07-25 | $15.83K (+58.3%) started 2025-07-25 |
| 5Y ago | $25.63K (+156.3%) started 2021-07-26 | $1.61K (-83.9%) started 2021-07-26 |
| 10Y ago | $29.37K (+193.7%) started 2016-07-25 | $29.07K (+190.7%) started 2018-12-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | GILD | MRNA |
|---|---|---|
| Market cap | $166.72B | $24.53B |
| Trailing P/E | 18.27 | N/A |
| Forward P/E | 13.83 | -15.03 |
| Price/Sales | 4.87 | N/A |
| EV/Revenue | 6.02 | 9.27 |
| Analyst target | $158.30 | $48.26 |
| Target upside | +17.89% | -21.93% |
| Metric | GILD | MRNA |
|---|---|---|
| Revenue growth | 4.40% | 260.20% |
| Earnings growth | 54.80% | N/A |
| EPS growth | +54.80% | N/A |
| FCF margin | +26.68% | -0.90% |
| Operating margin | 39.28% | -131.10% |
| Profit margin | 30.99% | -143.55% |
| ROIC proxy | 43.36% | -36.56% |
| Return on equity | 43.36% | -36.56% |
| Dividend yield | 2.44% | N/A |
| Beta | 0.34 | 0.94 |
| Debt/equity | 94.64 | 17.52 |
| Current ratio | 1.97 | 2.41 |
| Quick ratio | 1.54 | 2.23 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | GILD | MRNA |
|---|---|---|---|
| 1Y | Growth | +11.28% | +58.33% |
| CAGR | +11.32% | +58.55% | |
| Sharpe ratio | 0.37 | 0.94 | |
| Max drawdown | 22.03% | 34.52% | |
| Max daily drop | 3.72% | 10.83% | |
| Max wkly drop | 5.98% | 19.17% | |
| 5Y | Growth | +118.46% | -83.90% |
| CAGR | +16.93% | -30.62% | |
| Sharpe ratio | 0.58 | -0.28 | |
| Max drawdown | 26.59% | 95.38% | |
| Max daily drop | 10.15% | 21.01% | |
| Max wkly drop | 9.78% | 33.81% | |
| 10Y | Growth | +101.37% | +190.70% |
| CAGR | +7.25% | +15.01% | |
| Sharpe ratio | 0.23 | 0.49 | |
| Max drawdown | 30.47% | 95.38% | |
| Max daily drop | 10.15% | 21.01% | |
| Max wkly drop | 12.29% | 33.81% |
| Category | GILD | MRNA |
|---|---|---|
| Company | GILD | MRNA |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.